Savolitinib
As of the edition of 20 October 2026, Savolitinib is a small molecule: in active development; acts on MET.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2028
- Kind
- Small molecule
- Registered trials
- 48, 2 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Urinary and reproductive; Pregnancy and women's health; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MET | Hepatocyte growth factor receptor | P08581 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 18 | 15 | 2 | 1 |
| Phase 2 | 24 | 8 | 12 | 1 |
| Phase 3 | 6 | 2 | 4 | 0 |
| All trials | 48 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Hutchmed | Lead sponsor of trials | 2012 to now |
| AstraZeneca | Lead sponsor of trials | 2014 to now |